Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma
Provided By PR Newswire
Last update: Aug 16, 2022
SAN FRANCISCO, Aug. 16, 2022 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in Blood Advances, the open-access journal of the American Society of Hematology, highlighting the effects of NKTR-255, a novel polymer-conjugated human IL-15, on natural killer (NK) cell function and proliferation in multiple myeloma (MM).
Read more at prnewswire.com24.41
-0.6 (-2.4%)
Find more stocks in the Stock Screener
NKTR Latest News and Analysis
20 days ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
21 days ago - ChartmillLet's have a look at the top gainers and losers in the middle of the day of today's session.Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
21 days ago - ChartmillWhich stocks are gapping on Tuesday?Traders are paying attention to the gapping stocks in Tuesday's session. Let's dive into which stocks are experiencing notable gaps.
21 days ago - ChartmillTuesday's pre-market session: top gainers and losersDiscover the top movers in Tuesday's pre-market session and stay informed about market dynamics.
